From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
基本信息
- 批准号:10453790
- 负责人:
- 金额:$ 94.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-04 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressB-LymphocytesBiologyCellsClinicalDevelopmentGene ExpressionGenesGeneticGenomeGoalsHumanLymphomaLymphomagenesisMalignant - descriptorMalignant NeoplasmsMutationPathogenesisPhenotypePhysiologyPreclinical TestingReactionRegulationResearch Project SummariesRoleSignal PathwaySignaling ProteinStructure of germinal center of lymph nodeTherapeutic Interventionbaseexperiencelarge cell Diffuse non-Hodgkin&aposs lymphomamouse modelnew technologynew therapeutic targetprogramstherapeutic candidatetumor
项目摘要
Project Summary
This research program is aimed at identifying new pathogenetic mechanisms in Diffuse Large B-Cell
Lymphoma (DLBCL), the most common human lymphoma, as a mean to discover new targets for therapeutic
intervention. DLBCL is a heterogeneous malignancy comprising genetically and clinically distinct phenotypes,
which are derived from the malignant transformation of germinal center (GC) B cells at different stages of
differentiation. Recent analysis of the DLBCL genome has identified a multitude of altered genes, most of
which with unknown roles in normal GC physiology and lymphomagenesis. Thus, our program will address
these issues by two main complementary approaches. First, we will use novel technologies allowing the
analysis of signaling pathways and gene expression on a single cell basis from purified GC B cell
subpopulations, as a mean to comprehensively identify the programs that are involved in GC development and
potentially altered in DLBCL. Second, we will investigate the function and regulation of two GC “master
regulators”, the activity of which is deregulated in DLBCL via mutational mechanisms as well as via alterations
in “upstream” signaling pathways. The overall program is based on our long-standing experience in studying
the biology of the GC reaction in relationship to the genetic mechanisms leading to its malignant
transformation. We expect that the results of the above studies will identify new targets for therapy, which will
be eventually tested pre-clinically in our portfolio of genetically defined mouse models of DLBCL.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Riccardo Dalla-Favera其他文献
Riccardo Dalla-Favera的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Riccardo Dalla-Favera', 18)}}的其他基金
From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma
弥漫性大B细胞淋巴瘤从发病机制到新的治疗靶点
- 批准号:
10737214 - 财政年份:2023
- 资助金额:
$ 94.08万 - 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
- 批准号:
9528531 - 财政年份:2016
- 资助金额:
$ 94.08万 - 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
- 批准号:
9186876 - 财政年份:2016
- 资助金额:
$ 94.08万 - 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
- 批准号:
9977975 - 财政年份:2016
- 资助金额:
$ 94.08万 - 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
- 批准号:
10224858 - 财政年份:2016
- 资助金额:
$ 94.08万 - 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
- 批准号:
9326271 - 财政年份:2016
- 资助金额:
$ 94.08万 - 项目类别:
Role of MEF2B mutations in lymphomagenesis
MEF2B 突变在淋巴瘤发生中的作用
- 批准号:
8697703 - 财政年份:2014
- 资助金额:
$ 94.08万 - 项目类别:
Role of MEF2B mutations in lymphomagenesis
MEF2B 突变在淋巴瘤发生中的作用
- 批准号:
8849397 - 财政年份:2014
- 资助金额:
$ 94.08万 - 项目类别:
The Role of NOTCH1 in the Pathogenesis of CLL.
NOTCH1 在 CLL 发病机制中的作用。
- 批准号:
8539207 - 财政年份:2013
- 资助金额:
$ 94.08万 - 项目类别:
相似海外基金
Characterizing RNA regulation in B lymphocytes
B 淋巴细胞中 RNA 调控的特征
- 批准号:
502601 - 财政年份:2024
- 资助金额:
$ 94.08万 - 项目类别:
Characterization of Streptococcus suis interactions with B lymphocytes
猪链球菌与 B 淋巴细胞相互作用的表征
- 批准号:
573206-2022 - 财政年份:2022
- 资助金额:
$ 94.08万 - 项目类别:
University Undergraduate Student Research Awards
Altered B lymphocytes Due to Tungstate Exposure
钨酸盐暴露导致 B 淋巴细胞发生改变
- 批准号:
RGPIN-2020-05899 - 财政年份:2022
- 资助金额:
$ 94.08万 - 项目类别:
Discovery Grants Program - Individual
The regulation of signaling and cytoskeletal rearrangements in B-lymphocytes
B 淋巴细胞信号传导和细胞骨架重排的调节
- 批准号:
RGPIN-2019-04911 - 财政年份:2022
- 资助金额:
$ 94.08万 - 项目类别:
Discovery Grants Program - Individual
Myocardial-associated B lymphocytes and inflammatory injury
心肌相关B淋巴细胞与炎症损伤
- 批准号:
10543825 - 财政年份:2022
- 资助金额:
$ 94.08万 - 项目类别:
Myocardial-associated B lymphocytes and inflammatory injury
心肌相关B淋巴细胞与炎症损伤
- 批准号:
10339541 - 财政年份:2022
- 资助金额:
$ 94.08万 - 项目类别:
Exploring RNA helicase DDX the role of the1 at the crossroad of DNA repair processes in B lymphocytes
探索 RNA 解旋酶 DDX 在 B 淋巴细胞 DNA 修复过程十字路口的作用
- 批准号:
BB/X511560/1 - 财政年份:2022
- 资助金额:
$ 94.08万 - 项目类别:
Training Grant
Role and regulation of extracellular vesicles generated in response to stimulation of CD24 on B lymphocytes
B 淋巴细胞上 CD24 刺激产生的细胞外囊泡的作用和调节
- 批准号:
RGPIN-2022-03800 - 财政年份:2022
- 资助金额:
$ 94.08万 - 项目类别:
Discovery Grants Program - Individual